SILO PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.85 USD | 0.00% |
|
0.00% | +28.47% |
| Apr. 23 | Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment | CI |
| Apr. 10 | Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 10.55 | 4.466 | 5.261 | - | - |
| Enterprise Value (EV) 1 | 10.55 | 4.466 | 5.261 | 5.261 | 5.261 |
| P/E ratio | -1.96 x | -1.2 x | -3.3 x | -2.64 x | -2.57 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 61.9 x | 73.1 x | 73.1 x | 73.1 x |
| EV / Revenue | - | 61.9 x | 73.1 x | 73.1 x | 73.1 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 3,139 | 3,101 | 2,844 | - | - |
| Reference price 2 | 3.360 | 1.440 | 1.850 | 1.850 | 1.850 |
| Announcement Date | 3/24/23 | 3/25/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 0.0721 | 0.072 | 0.072 | 0.072 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -3.856 | -4.47 | -9.386 | -16.82 |
| Operating Margin | - | -5,347.56% | -6,208.33% | -13,036.11% | -23,356.94% |
| Earnings before Tax (EBT) 1 | - | -3.631 | -4.04 | -8.926 | -16.32 |
| Net income 1 | -3.909 | -3.701 | -4.04 | -8.926 | -16.32 |
| Net margin | - | -5,132.7% | -5,611.11% | -12,397.22% | -22,673.61% |
| EPS 2 | -1.710 | -1.202 | -0.5600 | -0.7000 | -0.7200 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/24/23 | 3/25/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 |
|---|---|---|
| Net sales 1 | 0.018 | 0.018 |
| EBITDA | - | - |
| EBIT 1 | -0.7734 | -1.164 |
| Operating Margin | -4,289.52% | -6,454.35% |
| Earnings before Tax (EBT) 1 | -0.6602 | -1.052 |
| Net income 1 | -0.6602 | -1.121 |
| Net margin | -3,661.45% | -6,218.41% |
| EPS 2 | -0.2100 | -0.3816 |
| Dividend per Share | - | - |
| Announcement Date | 11/13/23 | 3/25/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 3/24/23 | 3/25/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.85
USD
Average target price
10
USD
Spread / Average Target
+440.54%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +28.47% | 5.26M | |
| +1.45% | 40.51B | |
| -15.94% | 31.67B | |
| +52.66% | 24.62B | |
| -14.50% | 15.65B | |
| -14.38% | 12.07B | |
| -9.12% | 11.97B | |
| -42.56% | 11.61B | |
| +4.87% | 8.81B | |
| -4.33% | 8.5B |
- Stock Market
- Equities
- SILO Stock
- Financials Silo Pharma, Inc.
